Naranie Shanmuganathan

Adelaide, SA, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Mitochondrial DNA mutations are associated with impaired oxidative phosphorylation and enhanced imatinib response in chronic myeloid leukemia.

Mitochondrial DNA mutations are associated with impaired oxidative phosphorylation and enhanced imatinib response in chronic myeloid leukemia.

Journal: HemaSphere

Published: March 18, 2026

Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinib.

Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinib.

Journal: Leukemia

Published: March 10, 2026

Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.

Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.

Journal: Current hematologic malignancy reports

Published: January 14, 2026

Long-Term Survival Gains after Allogeneic Hematopoietic Stem Cell Transplant are Driven by Reductions in Non-Relapse Mortality: A 35-Year Statewide Australian Cohort Study.

Long-Term Survival Gains after Allogeneic Hematopoietic Stem Cell Transplant are Driven by Reductions in Non-Relapse Mortality: A 35-Year Statewide Australian Cohort Study.

Journal: Transplantation and cellular therapy

Published: November 13, 2025

Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients.

Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients.

Journal: HemaSphere

Published: October 23, 2025

Clinical and biological predictors of treatment-free remission in CML.

Clinical and biological predictors of treatment-free remission in CML.

Journal: Leukemia & lymphoma

Published: October 10, 2025

The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia.

The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia.

Journal: British journal of haematology

Published: September 14, 2025

How will genomic testing impact a clinician's choice for managing chronic myeloid leukemia?

How will genomic testing impact a clinician's choice for managing chronic myeloid leukemia?

Journal: Expert review of hematology

Published: July 10, 2025

Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations.

Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations.

Journal: Blood

Published: June 06, 2025

Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML.

Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML.

Journal: Leukemia

Published: May 21, 2025

Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia?

Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia?

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: April 24, 2025

Enhanced Detection of Splice-Altering Variants in Hematologic Malignancies Using Targeted RNA-Sequencing Data.

Enhanced Detection of Splice-Altering Variants in Hematologic Malignancies Using Targeted RNA-Sequencing Data.

Journal: The Journal of molecular diagnostics : JMD

Published: February 25, 2025

Showing 1-12 of 55

Last Updated: 09/26/2026